CD4+CD25+CD127low regulatory T cells play predominant anti-tumor suppressive role in hepatitis B virus-associated hepatocellular carcinoma

Frontiers in Immunology

Volumn 6, Issue FEB, 2015, Pages

  Sharma, Shreya ^a   Khosla, Ritu ^a   David, Paul ^a   Rastogi, Archana ^a   Vyas, Ashish ^a   Singh, Dileep ^a   Bhardwaj, Ankit ^a   Sahney, Amrish ^a   Maiwall, Rakhi ^a   Sarin, Shiv Kumar ^a   Trehanpati, Nirupma ^a  

^a INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

Author keywords

Alpha fetoprotein; Hepatitis B virus; Hepatocellular carcinoma; T regulatory cells; Transforming growth factor

Indexed keywords

BETA CATENIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 7 RECEPTOR; NOTCH RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER INHIBITION; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LIVER BIOPSY; LIVER CELL CARCINOMA; MALE; NONALCOHOLIC FATTY LIVER; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

EID: 84926628558     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00049     Document Type: Article

References (30)

1. Thun MJ. The global burden of cancer: priorities for prevention. Carcinogenesis (2010) 31(1):100-10. doi: 10.1093/carcin/bgp263
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol (2006) 45:529-38. doi:10.1016/j.jhep.2006.05.013
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer Statistics, 2008. CA. Cancer J Clin (2008) 58:71-96. doi:10.3322/CA.2007.0010
4. Evans AA, London WT, Gish RG, Cohen C, Block TM. Chronic HBV infection outside treatment guidelines: is treatment needed? Antivir Ther (2013) 18(2):229-35. doi:10.3851/IMP2325
5. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol (1995) 13:29-60. doi:10.1146/annurev.iy.13.040195.000333
6. Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M, et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci USA (2010) 107(2):798-802. doi:10.1073/pnas.0913498107
7. Corthay A. How do regulatory T cells work? Scand J Immunol (2009) 70(4):326-36. doi:10.1111/j.1365-3083.2009.02308.x
8. Jonuleit H, Schmitt E. The regulator T cell family: distinct subsets and their interrelations. J Immunol (2003) 171(12):6323-7. doi:10.4049/jimmunol.171.12.6323
9. Wan YY, Flavell RA. TGF-β and regulatory T cell in immunity and autoimmunity. J Clin Immunol (2008) 28(6):647-59. doi:10.1007/s10875-008-9251-y
10. Asano N, Watanabe T, Kitani A, Fuss IJ, Strober W. Notch1 signaling and regulatory T cell function. J Immunol (2008) 180:2796-804. doi:10.4049/jimmunol.180.5.2796
11. Ding Y, Shen S, Lino AC, Curotto de Lafaille MA, Lafaille JJ. Beta catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells. Nat Med (2008) 14(2):162-9. doi:10.1038/nm1707
12. Trehanpati N, Shrivastav S, Shivakumar B, Khosla R, Bhardwaj S, Chaturvedi J, et al. Analysis of notch and TGF-β signaling expression in different stages of disease progression during hepatitis B virus infection. Clin Transl Gastroenterol (2012) 3:e23. doi:10.1038/ctg.2012.17
13. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res (2005) 65(6):2457-64. doi:10.1158/0008-5472.CAN-04-3232
14. Boettler T, Spangenberg HC, Neumann-Haefelin C, Panther E, Urbani S, Ferrari C, et al. T cells with a CD4+ CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol (2005) 79:7860-7. doi:10.1128/JVI.79.12.7860-7867.2005
15. El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol (2006) 8:234-43. doi:10.1215/15228517-2006-006
16. Trehanpati N, Hissar S, Shrivastav S, Sarin SK. Immunological mechanisms of hepatitis B virus persistence in newborns. Indian J Med Res (2013) 138(5): 700-10.
17. El-Badawy O, Sayed D, Badary MS, Abd-Alrahman ME, El-Feky MA, Thabit AG. Relations of regulatory T cells with hepatitis markers in chronic hepatitis B virus infection. Hum Immunol (2012) 73(4):335-41. doi:10.1016/j.humimm.2012.01.014
18. Schmitt EG, Williams CB. Generation and function of induced regulatory T cells. Front Immunol (2013) 4:152. doi:10.3389/fimmu.2013.00152
19. Zhang HH, Mei MH, Fei R, Liu F, Wang JH, Liao WJ, et al. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. J Viral Hepat (2010) 17(Suppl 1):34-43. doi:10.1111/j.1365-2893.2010.01269.x
20. Peng G, Li S, Wu W, Sun Z, Chen Y, Chen Z. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology (2008) 123(1):57-65. doi:10.1111/j.1365-2567.2007.02691.x
21. Piconese S, Timperi E, Barnaba V. Hardcore' OX40+ immunosuppressive regulatory Tcells in hepatic cirrhosis and cancer. Oncoimmunology (2014) 3:e29257. doi:10.4161/onci.29257
22. Yu X, Guo R, Ming D, Su M, Lin C, Deng Y, et al. Ratios of regulatory T cells/T-helper 17 cells and transforming growth factor-β1/interleukin-17 to be associated with the development of hepatitis B virus-associated liver cirrhosis. J Gastroenterol Hepatol (2014) 29(5):1065-72. doi:10.1111/jgh.12459
23. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology (2007) 132:2328-39. doi:10.1053/j.gastro.2007.03.102
24. Yang J, Zhang JX, Wang H, Wang GL, Hu QG, Zheng QC. Hepatocellular carcinoma and macrophage interaction induced tumor immunosuppression via Treg requires TLR4 signaling. World J Gastroenterol (2012) 18(23):2938-47. doi:10.3748/wjg.v18.i23.2938
25. El Bassuoni MA, Obada MA, Korah T, El Sayed S. Assessment of Treg Cells CD4+CD25+ in chronic cirrhotic liver disease and hepatocellular carcinoma Egyptian patients. Hepatitis Monthly (2008) 8(3):173-7.
26. Huang Y, Wang FM, Wang T, Wang YJ, Zhu ZY, Gao YT, et al. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients. Digestion (2012) 86(4):329-37. doi:10.1159/000342801
27. Horwitz DA, Zheng SG, Wang J, Gray JD. Critical role of IL-2 and TGF-beta in generation, function and stabilization of Foxp3+CD4+ Treg. Eur J Immunol (2008) 38(4):912-5. doi:10.1002/eji.200738109
28. Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. Natural and induced CD4+CD25+ cells educate CD4+CD25-cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol (2004) 172(9):5213-21.
29. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol (2005) 78(5):1043-51. doi:10.1189/jlb.0705358
30. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med (2013) 2(5):662-73. doi:10.1002/cam4.106